

JUL 07 2004

001



Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	See Schedule A
		Filing Date	See Schedule A
		First Named Inventor	See Schedule A
		Group Art Unit	2004 JUL 7 P 12-21
		Examiner Name	USPTO
Total Number of Pages In This Submission	1	Attorney Docket Number	See Schedule A

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR: 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. <div style="text-align: center; font-size: 2em; opacity: 0.5;">OFFICIAL</div>	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm and Individual name	Morgan, Lewis & Bockius LLP Todd W. Esker Reg No. 46,690
Signature	
Date	June 15, 2004

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Kathryn A. Degliantoni
Signature	
Date	June 15, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1256488 v1

JUL 07 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application of: See Attached Schedule A
Serial No.: See Attached Schedule A
Filed: See Attached Schedule A
For: See Attached Schedule A

Attorney Docket No: See Attached
Schedule A

09/855320 OFFICIAL

REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R:

Neose Technologies, Inc., owner of the entire right, title and interest in, to and under the inventions listed in the attached Schedule hereby revokes all previous powers of attorney and appoints Morgan, Lewis & Bockius LLP, customer no. 43850, and each of them, its attorneys, to prosecute these matters, and to transact all business in the Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Morgan, Lewis & Bockius LLP as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all future correspondence to Customer Number 43850, Morgan, Lewis & Bockius LLP, located at 3300 Hillview Avenue, Palo Alto, California 94304, and direct all telephone calls to Morgan, Lewis & Bockius LLP at (650) 493-4935.

Date:

June 14, 2004

Assignee: Neose Technologies, Inc.

Signature:

Typed Name: Debra Poul, Esq.

Position/Title: Senior Vice President, General
Counsel and SecretaryAddress: 102 Witmer Road
Horsham, PA 19044

SCHEDULE A

Serial No./ Patent No.	Filing Date/ Issue Date	Title	First Named Inventor	Docket No.
60/468,374	May 5, 2003	Cyclodextrin Affinity Purification of Starch-Binding- Domain Tagged	Villafranca, Joseph John	40853-01-5100-PR
60/535,290	January 8, 2004	Compositions and Methods for the Preparation of Human Growth Hormone Glycosylation Mutants	DeFrees, Shawn	40853-01-5101-PR
60/544,440	February 12, 2004	Compositions and Methods for the Preparation of Human Growth Hormone Glycosylation Mutants	DeFrees, Shawn	40853-01-5101-P1
10/487,841	February 17, 2004	Novel Synthetic Ganglioside Derivatives and Compositions Thereof	DeFrees, Shawn	40853-01-5104
10/485,195	January 27, 2004	Neutral Glycosphingolipids and Glycosyl- Sphingosines and Methods for Isolating the Same	DeFrees, Shawn	40853-01-5105
09/123,251	July 27, 1998	Topical Compositions Containing Sialyl Sugars and Their Derivatives	Anderson, Jon E.	40853-01-5106
08/947,775 6,454,946	October 9, 1997 September 24, 2002	Carbohydrate Purification Using Ultrafiltration, Reverse Osmosis and Nanofiltration	DeFrees, Shawn	40853-01-5107
10/104,609	March 22, 2002	Carbohydrate Purification Using Ultrafiltration, Reverse Osmosis and Nanofiltration	DeFrees, Shawn	40853-01-5107-01

10/184,211	June 27, 2002	Carbohydrate Purification Using Ultrafiltration, Reverse Osmosis and Nanofiltration	DeFrees, Shawn	40853-01-5107-02
09/855,320	May 14, 2001	In Vitro Modification of Glycosylation Patterns of Recombinant Glycopeptides	Bayer, Robert J.	40853-01-5108
10/198,806	July 19, 2002	In Vitro Modification of Glycosylation Patterns of Recombinant Glycopeptides	Bayer, Robert J.	40853-01-5108-01
10/219,197	August 13, 2002	In Vitro Modification of Glycosylation Patterns of Recombinant Glycopeptides	Bayer, Robert J.	40853-01-5108-02
10/391,035	March 17, 2003	In Vitro Modification of Glycosylation Patterns of Recombinant Glycopeptides	Bayer, Robert J.	40853-01-5108-03
09/935,363 6,440,703	August 22, 2001 August 27, 2002	Enzymatic Synthesis of Gangliosides	DeFrees, Shawn	40853-01-5114-01
10/485,892	February 4, 2004	Chemo-Enzymatic Synthesis of Sialylated Oligosaccharides	McGuire, Edward J.	40853-01-5122
60/490,168	July 25, 2003	Antibody-Toxin Conjugates	DeFrees, Shawn	40853-01-5128-PR
60/499,448	September 2, 2003	Antibody-Toxin Conjugates	DeFrees, Shawn	40853-01-5128-P1
60/474,094	May 29, 2003	Compositions and Methods for the Preparation and Conjugation of Biantennary Polymers Including Polyethylene Glycol	DeFrees, Shawn	40853-01-5133-P1
60/509,752	October 7, 2003	Functionalized Poly (Ethylene Glycol)	DeFrees, Shawn	40853-01-5137-PR

60/535,284	January 8, 2004	O-Linked Glycosylation of Peptides	DeFrees, Shawn	40853-01-5138-PR
60/544,411	February 12, 2004	O-Linked Glycosylation of Peptides	DeFrees, Shawn	40853-01-5138-P1
60/546,631	February 20, 2004	O-Linked Glycosylation of Peptides	DeFrees, Shawn	40853-01-5138-P2
TO BE ASSIGNED	May 12, 2004	O-Linked Glycosylation of Peptides	DeFrees, Shawn	40853-01-5138-P3
60/524,989	November 24, 2003	Glycopegylated Erthropoietin	DeFrees, Shawn	40853-01-5142-PR
60/555,504	March 22, 2004	Glycopegylated Erthropoietin	DeFrees, Shawn	40853-01-5142-P1
60/527,089	December 3, 2003	Glycopegylated Human Factor IX	Bayer, Robert	40853-01-5144-PR
60/526,796	December 3, 2003	Glycopegylated Granulocyte Colony Stimulating Factor	DeFrees, Shawn	40853-01-5145-PR
TO BE ASSIGNED	May 11, 2004	Glycopegylated Granulocyte Colony Stimulating Factor	DeFrees, Shawn	40853-01-5145-P1
60/527,082	December 3, 2003	Glycopegylated Human Follicle Stimulating Hormone	DeFrees, Shawn	40853-01-5146-PR
60/539,387	January 26, 2004	PEG-ylated Nucleotide Sugars	DeFrees, Shawn	40853-01-5147-PR